Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

ANCHOR trial conclusions regarding the effects of pure eicosapentaenoic acid on low-density lipoprotein cholesterol.

Baum SJ.

Am J Cardiol. 2013 Feb 1;111(3):454-5. doi: 10.1016/j.amjcard.2012.11.035. No abstract available.

PMID:
23317530
2.

Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).

Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN.

Am J Cardiol. 2012 Oct 1;110(7):984-92. doi: 10.1016/j.amjcard.2012.05.031. Epub 2012 Jul 20.

PMID:
22819432
3.

Authors' reply.

Ballantyne CM, Bays HE, Braeckman RA, Soni PN.

Am J Cardiol. 2013 Feb 1;111(3):455-6. doi: 10.1016/j.amjcard.2012.11.036. No abstract available.

PMID:
23317532
4.

High-density lipoprotein cholesterol and triglycerides in the statin era: a pending issue?

Paillard F.

Arch Cardiovasc Dis. 2009 Mar;102(3):165-7. doi: 10.1016/j.acvd.2008.12.001. Epub 2009 Feb 23. No abstract available.

5.

Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).

Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN.

Am J Cardiol. 2011 Sep 1;108(5):682-90. doi: 10.1016/j.amjcard.2011.04.015. Epub 2011 Jun 16.

PMID:
21683321
6.

Drugs for hypertriglyceridemia.

[No authors listed]

Med Lett Drugs Ther. 2013 Mar 4;55(1411):17-9. No abstract available.

PMID:
23467119
7.

A new pure ω-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial.

Jacobson TA.

Expert Rev Cardiovasc Ther. 2012 Jun;10(6):687-95. doi: 10.1586/erc.12.56.

PMID:
22894624
8.

Assessing the clinical benefits of lipid-disorder drugs.

Hiatt WR, Smith RJ.

N Engl J Med. 2014 Jan 30;370(5):396-9. doi: 10.1056/NEJMp1313866. No abstract available.

10.

Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia.

Nakamura N, Hamazaki T, Ohta M, Okuda K, Urakaze M, Sawazaki S, Yamazaki K, Satoh A, Temaru R, Ishikura Y, Takata M, Kishida M, Kobayashi M.

Int J Clin Lab Res. 1999;29(1):22-5.

PMID:
10356659
11.

Clinical overview of algal-docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors.

Ryan AS, Keske MA, Hoffman JP, Nelson EB.

Am J Ther. 2009 Mar-Apr;16(2):183-92. doi: 10.1097/MJT.0b013e31817fe2be. Review.

PMID:
19145206
12.

Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?

Scherer DJ, Nicholls SJ.

Vasc Health Risk Manag. 2015 Mar 25;11:203-9. doi: 10.2147/VHRM.S40134. eCollection 2015. Review.

13.

Low-density lipoprotein reduction: is the risk worth the benefit?

Sabharwal AK, Boord JB.

Curr Atheroscler Rep. 2006 Jan;8(1):19-25. Review.

PMID:
16455010
14.

Triglycerides: a case for treatment?

Wierzbicki AS, Clarke RE, Viljoen A, Mikhailidis DP.

Curr Opin Cardiol. 2012 Jul;27(4):398-404. doi: 10.1097/HCO.0b013e328353adc1. Review.

PMID:
22565137
15.

Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.

Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN; COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators.

Clin Ther. 2007 Jul;29(7):1354-67.

PMID:
17825687
16.

To treat or not to treat? Questions, controversies in prevention.

Caffrey MK.

Am J Manag Care. 2014 May;20(8 Spec No.):E11. No abstract available.

17.

Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia.

Isaacsohn J, Hunninghake D, Schrott H, Dujovne CA, Knopp R, Weiss SR, Bays H, Crouse JR 3rd, Davidson MH, Keilson LM, McKenney J, Korenman SG, Dobs AS, Stein E, Krauss RM, Maccubbin D, Cho M, Plotkin DJ, Mitchel YB.

Clin Cardiol. 2003 Jan;26(1):18-24.

18.

Triglycerides and risk for coronary artery disease.

McBride P.

Curr Atheroscler Rep. 2008 Oct;10(5):386-90. Review.

PMID:
18706279
19.

Hypertriglyceridemia: associated risks and effect of drug treatment.

Jonkers IJ, Smelt AH, van der Laarse A.

Am J Cardiovasc Drugs. 2001;1(6):455-66. Review.

PMID:
14728004
20.
Items per page

Supplemental Content

Write to the Help Desk